

External associations and certifications

Centrient Pharmaceuticals works with external platforms and associations on matters related to ESG, including:



As a founding member of the AMR IA, we are committed to combatting the spread of antimicrobial resistance across the pharmaceutical value chain.



As a member of PSCI since 2016, we commit to promoting responsible supply chain management and better business conditions across the industry. We actively participate in several PSCI forums.



We received Ecovadis Gold Sustainability Rating in 2023 for the fourth year in a row

The EcoVadis Gold Rating affirms our commitment to environmental and social sustainability and underlines our position as a sustainable leader in the generics pharmaceutical industry.

The Gold Sustainability Rating ranks Centrient Pharmaceuticals in the top 4% of the companies assessed by EcoVadis in the manufacture of basic pharmaceutical products and pharmaceutical preparations industry.

ISO 14001 accreditation of all Centrient sites

All Centrient sites are now certified to the ISO 14001: 2015 standard for Environmental Management Systems.

Read more in our 2023 ESG report: [here](#)

Who we are

Centrient Pharmaceuticals is a key global business-to-business player in sustainable, enzymatic antibiotics, next-generation statins and anti-fungals. We produce and sell intermediates and active pharmaceutical ingredients (APIs), as well as our own tablets, capsules and other finished dosage forms (FDFs).

Our presence

We are headquartered in Rotterdam, the Netherlands, the country where the company was founded in 1869, more than 150 years ago. Our global network of manufacturing sites comprises six facilities across North America, Europe and Asia.

Our ESG Ambition 2021-2030

Following the successful implementation of the sustainability Roadmap 2008-2020, Centrient Pharmaceuticals has set its sights higher, aiming to become an ESG leader in the generic pharmaceutical industry. By producing sustainably, we safeguard our product quality and reliability and help support the well-being of the planet and all living on it.

2030 ESG Goals

Our ESG Ambition 2021–2030 strengthens our focus on the topics we view as most critical to our business and stakeholders in areas where we can make the greatest impact.

PureActives® - The enzymatic difference

Our PureActives are manufactured using our patented enzymatic platform. This enzymatic platform completely replaces the traditional 13-step antibiotic production process with natural processes that eliminate the use of solvents or other chemicals. We take pride in knowing that our PureActives are the world's purest and most environmentally friendly produced APIs and finished dosage forms.

Copyright © 2024 Centrient Pharmaceuticals. All rights reserved.

Although all reasonable and diligent care has been used to ensure that the information provided herein is accurate, complete and up-to-date, nothing contained herein shall, or may, be construed to imply any representation or warranty of any kind and no representation or warranty of any is given, whether express or implied, by the Centrient Pharmaceuticals or by any other person with respect to the matters set out in the ESG Report. This includes regarding the accuracy, interpretation, application, fairness, sufficiency, use, reliability, adequacy, achievability, or reasonableness of any statement, claim, purported fact or financial amount, prediction, projection, estimate, forecast or expectation or figure quoted, or of any other information, or of the assumptions or information on which any such information is based. No reliance should be placed on such information. Neither the Centrient Pharmaceuticals nor any of its respective directors, officers, employees, affiliates, direct or indirect shareholders, advisors, agents or any other person shall be liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on any statement in, or omission from, the ESG Report. Any such liability is expressly excluded.

Centrient Pharmaceuticals ESG Report 2023 Highlights



Environmental

Targets

- + **46.2%** absolute reduction in scope 1 and 2 greenhouse gas emissions and **27.5%** absolute reduction in scope 3 by 2031¹
- + **90%** of waste repurposed and landfill only if no viable alternative available by 2030
- + Source **50%** renewable electricity by 2030
- + **5%** reduction in water consumption intensity, maximise water recycling and look for options to reduce ground water use by 2030²
- + R&D projects pass Sustainability assessment (2025)³
- + Sites and suppliers compliant with AMR IA Common Manufacturing Framework and Predicted No-Effect Concentration targets

¹ Centrient commits to reduce absolute scope 1 and 2 GHG emissions 46.2% from 2022 as a base year and commit to reduce absolute scope 3 GHG emissions from purchased goods and services and fuel and energy-related activities 27.5% by 2031.

² From the baseline of 2015, refers to water withdrawal in our operations. Intensity 5% refers to total ML of water used over tonnes of product produce

³ Projects evaluated under our internal PMP Evaluation methodology

Social

Targets

- + Increasing access of our lifesaving antibiotics to **2 billion** patients by 2030
- + **50,000+** lives touched by Centrient global community programme annually by 2030
- + High level of employee engagement - in top **10%** for our industry (2025)
- + **50%** gender balance in senior management roles (2025)⁴
- + Inclusive leadership with less than **8%** voluntary attrition
- + Certified human and labour rights compliance in our operations (2024)⁵

⁴ Leadership roles refers to C43 and above positions on our internal scales

⁵ Certification scheme to be determined

Governance

Targets

- + Several diverse members at Board level, reflecting a balanced composition in accordance with legal requirements (2025)
- + **100%** of eligible employees committed to Code of Conduct (2024)
- + High standard of compliance for data privacy and security according to EU GDPR
- + Continued stakeholder collaboration on ESG topics such as AMR
- + High standard of compliance for ESG and financial transparency and disclosure (2025)
- + **75%** of top suppliers meet sustainability standards (2025)⁶

⁶ Centrient Internal Sustainable procurement standards as published: <https://shorturl.at/ahjDQ>

ESG Highlights 2023

At Centrient Pharmaceuticals, we believe safeguarding the environment is the only way forward for a company like ours.

Achieved key targets in line with our ESG Ambition 2021-2030:



*Compared to base year 2021



*Compared to base year 2015

Maintained 100% compliance with PNEC limits and certified our Spain site under new AMR IA scheme



Climate targets validated by the Science Based Targets initiative (SBTi)



Introduced shadow carbon pricing evaluation for our key investments



Reported data to the Carbon Disclosure Project for the first time in July 2023



For us, improving and saving lives is about more than producing and selling high-quality pharmaceuticals. We go above and beyond to create a positive impact for communities around the world. From India to Mexico, our Community Action (CA) programme is making a difference for people living in our local communities, delivering positive change across everything from health to renewable energy, and from education to employability

Facilitated 1.5 billion patient treatments globally (2023)



Increased gender balance at senior level, with 30% of senior management roles held by women



Launched a Centrient Community Action strategy and framework



Impacted more than 45,000 lives around the world through our CSR programme and activities



Established a Mobile Healthcare Unit in Toansa, India to provide medical facilities and services directly to the community, benefitting more than 1,200 people in 2023



Reached 2,500 people impacted by the 2023 Toansa flooding by distributing essential medicines and hygiene kits, and by hosting sessions to create awareness around water-borne diseases



As a key market player in foundational medicines, we commit to ensuring a high standard of transparency and professional ethics. We safeguard patient safety through strict product quality management and only work with responsible suppliers and CMOs.

97% of all eligible employees completed Code of Conduct certification (2023)



Completed the Human Rights Impact assessment



Maintained our Gold rating for EcoVadis Supplier Assessment in 2022 and 2023, ranking in top 4% of companies assessed

Developed and established a Sustainable Sourcing Policy

